Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • High SVR rates with 12 weeks of elbasvir/grazoprevir in treatment-naive patients with genotypes 1, 4, 5, or 6 HCV infection
    • C-EDGE-TN: SVR12 rate 95% in patients with genotype 1, 4, or 6 HCV infection[Zeuzem 2015]
    • C-SCAPE: better efficacy of elbasvir/grazoprevir regimen with vs without ribavirin in noncirrhotic patients with genotype 5 HCV infection, with comparable efficacy in genotype 6 HCV infection[Brown 2018]

Action required